Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Guillain-Barré Syndrome | Case report

Severe Guillain-Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report

Authors: Alexandre Chlilek, Claire Roger, Laurent Muller, Marie-Josée Carles, Robin Stephan, Didier Laureillard, Jean-Philippe Lavigne, Jean-Yves Lefrant, Albert Sotto

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

We describe a case of severe Guillain-Barre syndrome (GBS) associated with chronic active hepatitis C and mixed cryoglobulinemia (MC). To our knowledge, this association between GBS and hepatitis C virus (HCV) infection has been rarely reported.

Case presentation

A 56-year-old man developed symmetrical muscle weakness in all extremities, areflexia and sensorial disorder followed by acute respiratory failure associated with chronic active hepatitis C, which was confirmed by the presence of anti-HCV antibodies in the serum and persistence of HCV RNA viral load for more than 6 months. Chronic hepatitis C was further complicated by type 3 MC. Electromyography showed peripheral nerve injury (mainly in axon). A severe acute motor sensory axonal neuropathy (AMSAN) was diagnosed. After treatment with intravenous immunoglobulin and plasma exchange followed by antiviral therapy by direct-acting antiviral agent, patient showed progressive recovery and was transferred 3 months after his first admission to a rehabilitation center.

Conclusions

Our case reported a severe GBS associated with HCV infection and MC. EMG classified for the first time the subtype of GBS (severe AMSAN) correlated with severe clinical form. HCV infection should be screened in high-risk patients to prevent silent progression of the chronic hepatitis C and its potentially severe extra-hepatic manifestations.
Literature
1.
go back to reference Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22(10):833–8.CrossRef Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22(10):833–8.CrossRef
2.
go back to reference Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(Suppl 1):S58–68.CrossRef Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(Suppl 1):S58–68.CrossRef
3.
go back to reference Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–73.CrossRef Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–73.CrossRef
4.
go back to reference Mathew S, Faheem M, Ibrahim SM, Iqbal W, Rauff B, Fatima K, et al. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8(12):545–56.CrossRef Mathew S, Faheem M, Ibrahim SM, Iqbal W, Rauff B, Fatima K, et al. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8(12):545–56.CrossRef
5.
go back to reference Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21(8):2269–80.CrossRef Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21(8):2269–80.CrossRef
6.
go back to reference Iriana S, Curry MP, Afdhal NH. Neurologic manifestations of hepatitis C virus infection. Clin Liver Dis. 2017;21(3):535–42.CrossRef Iriana S, Curry MP, Afdhal NH. Neurologic manifestations of hepatitis C virus infection. Clin Liver Dis. 2017;21(3):535–42.CrossRef
7.
go back to reference Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27.CrossRef Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27.CrossRef
8.
go back to reference van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82.CrossRef van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82.CrossRef
9.
go back to reference Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–9.CrossRef Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–9.CrossRef
10.
go back to reference De Klippel N, Hautekeete ML, De Keyser J, Ebinger G. Guillain-Barré syndrome as the presenting manifestation of hepatitis C infection. Neurology. 1993;43(10):2143.CrossRef De Klippel N, Hautekeete ML, De Keyser J, Ebinger G. Guillain-Barré syndrome as the presenting manifestation of hepatitis C infection. Neurology. 1993;43(10):2143.CrossRef
11.
go back to reference Zylberberg H, Hagège H, Roualdes B, Meyrignac C, Chousterman M. Guillain-Barré syndrome in a patient with chronic active hepatitis C. Gastroenterol Clin Biol. 1995;19(5):551.PubMed Zylberberg H, Hagège H, Roualdes B, Meyrignac C, Chousterman M. Guillain-Barré syndrome in a patient with chronic active hepatitis C. Gastroenterol Clin Biol. 1995;19(5):551.PubMed
12.
go back to reference Lacaille F, Zylberberg H, Hagège H, Roualdès B, Meyrignac C, Chousterman M, et al. Hepatitis C associated with Guillain-Barré syndrome. Liver. 1998;18(1):49–51.CrossRef Lacaille F, Zylberberg H, Hagège H, Roualdès B, Meyrignac C, Chousterman M, et al. Hepatitis C associated with Guillain-Barré syndrome. Liver. 1998;18(1):49–51.CrossRef
13.
go back to reference Massengo SA, Furby A, Stanescu C, Charasse C, Madigand M. Hepatitis C with cryoglobulinemia associated with Guillain-Barre syndromePresse Med. 2001;30(15):739.PubMed Massengo SA, Furby A, Stanescu C, Charasse C, Madigand M. Hepatitis C with cryoglobulinemia associated with Guillain-Barre syndromePresse Med. 2001;30(15):739.PubMed
14.
go back to reference Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(Pt 1):33–43.CrossRef Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(Pt 1):33–43.CrossRef
15.
go back to reference Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barré syndrome in northern China. Relationship to campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118 ( Pt 3):597–605.CrossRef Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barré syndrome in northern China. Relationship to campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118 ( Pt 3):597–605.CrossRef
16.
go back to reference Shahrizaila N, Yuki N. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action. Expert Opin Pharmacother. 2011;12(10):1551–60.CrossRef Shahrizaila N, Yuki N. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action. Expert Opin Pharmacother. 2011;12(10):1551–60.CrossRef
17.
go back to reference Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma exchange/Sandoglobulin Guillain-Barré syndrome trial group. Ann Neurol. 1998;44(5):780–8.CrossRef Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma exchange/Sandoglobulin Guillain-Barré syndrome trial group. Ann Neurol. 1998;44(5):780–8.CrossRef
18.
go back to reference Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012;123(8):1487–95.CrossRef Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012;123(8):1487–95.CrossRef
19.
go back to reference Shire NJ, Sherman KE. Epidemiology of hepatitis C virus. A Battle on New Frontiers. Gastroenterol Clin North Am. 2015;44(4):699–716.CrossRef Shire NJ, Sherman KE. Epidemiology of hepatitis C virus. A Battle on New Frontiers. Gastroenterol Clin North Am. 2015;44(4):699–716.CrossRef
20.
go back to reference Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):1145–60.CrossRef Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):1145–60.CrossRef
21.
go back to reference Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database Syst Rev. 2014;(12):CD010404. Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database Syst Rev. 2014;(12):CD010404.
22.
go back to reference Santoro L, Manganelli F, Briani C, Giannini F, Benedetti L, Vitelli E, et al. Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. J Neurol Neurosurg Psychiatry. 2006;77(5):626–9.CrossRef Santoro L, Manganelli F, Briani C, Giannini F, Benedetti L, Vitelli E, et al. Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. J Neurol Neurosurg Psychiatry. 2006;77(5):626–9.CrossRef
23.
go back to reference Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10(8):444–54.CrossRef Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10(8):444–54.CrossRef
24.
go back to reference Ramos-Casals M, Al Z, Ferri C, Brito-Zerón P, Retamozo S, Casato M, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282–99.CrossRef Ramos-Casals M, Al Z, Ferri C, Brito-Zerón P, Retamozo S, Casato M, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282–99.CrossRef
25.
go back to reference Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol. 2008;14(2):318–21.CrossRef Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol. 2008;14(2):318–21.CrossRef
26.
go back to reference Niazi MA, Azhar A, Tufail K, Feyssa EL, Penny SF, McGregory M, et al. Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: a case report. World J Hepatol. 2010;2(4):162–6.CrossRef Niazi MA, Azhar A, Tufail K, Feyssa EL, Penny SF, McGregory M, et al. Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: a case report. World J Hepatol. 2010;2(4):162–6.CrossRef
27.
go back to reference Macleod WN. Sporadic non-a, non-B hepatitis and Epstein-Barr hepatitis associated with the Guillain-Barré syndrome. Arch Neurol. 1987;44(4):438–42.CrossRef Macleod WN. Sporadic non-a, non-B hepatitis and Epstein-Barr hepatitis associated with the Guillain-Barré syndrome. Arch Neurol. 1987;44(4):438–42.CrossRef
28.
go back to reference Tabor E. Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. J Med Virol. 1987;21(3):207–16.CrossRef Tabor E. Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. J Med Virol. 1987;21(3):207–16.CrossRef
29.
go back to reference Gutzler F, Andrassy K, Kommerell B, Krieger D. Guillain-Barré polyneuropathy in Wegener’s granulomatosis with pulmonary-renal syndrome. Dtsch Med Wochenschr. 1990;115(10):372–7.CrossRef Gutzler F, Andrassy K, Kommerell B, Krieger D. Guillain-Barré polyneuropathy in Wegener’s granulomatosis with pulmonary-renal syndrome. Dtsch Med Wochenschr. 1990;115(10):372–7.CrossRef
30.
go back to reference Wakerley BR, Uncini A, Yuki N. GBS classification group, GBS classification group. Guillain-Barré and miller fisher syndromes--new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–44.CrossRef Wakerley BR, Uncini A, Yuki N. GBS classification group, GBS classification group. Guillain-Barré and miller fisher syndromes--new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–44.CrossRef
Metadata
Title
Severe Guillain-Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report
Authors
Alexandre Chlilek
Claire Roger
Laurent Muller
Marie-Josée Carles
Robin Stephan
Didier Laureillard
Jean-Philippe Lavigne
Jean-Yves Lefrant
Albert Sotto
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4278-7

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue